Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Keymed Biosciences, Inc. ( (HK:2162) ) just unveiled an update.
Keymed Biosciences Inc. has announced its upcoming Annual General Meeting scheduled for June 26, 2025, in Chengdu, China. The meeting will address several key resolutions, including the adoption of the 2024 financial statements, re-election of directors, and re-appointment of Ernst & Young as auditors. Additionally, the company seeks approval for the directors to issue new shares, which could impact its market position by potentially increasing capital for future projects.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative therapies. The company is known for its work in biopharmaceuticals, targeting various medical conditions with a strong emphasis on research and development.
YTD Price Performance: 36.73%
Average Trading Volume: 2,263,812
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$11.06B
See more data about 2162 stock on TipRanks’ Stock Analysis page.